Study of LP-184 in Patients With Advanced Solid Tumors

Study Summary

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Conditions

Advanced Solid Tumor Metastatic Solid Tumor GBM TNBC - Triple-Negative Breast Cancer NSCLC Pancreatic Adenocarcinoma DDR Gene Mutation

Interventions / Drugs

LP-184 Spironolactone Olaparib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment175 participants

Primary Completion—

Lead SponsorLantern Pharma Inc.

Data Retrieved2026-04-11 04:20:13.316930+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.